Deriving Schwann cells from hPSCs enables disease modeling and drug discovery for diabetic peripheral neuropathy
Majd H, Amin S, Ghazizadeh Z, Cesiulis A, Arroyo E, Lankford K, Majd A, Farahvashi S, Chemel A, Okoye M, Scantlen M, Tchieu J, Calder E, Le Rouzic V, Shibata B, Arab A, Goodarzi H, Pasternak G, Kocsis J, Chen S, Studer L, Fattahi F. Deriving Schwann cells from hPSCs enables disease modeling and drug discovery for diabetic peripheral neuropathy. Cell Stem Cell 2023, 30: 632-647.e10. PMID: 37146583, PMCID: PMC10249419, DOI: 10.1016/j.stem.2023.04.006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBupropionDiabetes MellitusDiabetic NeuropathiesDrug DiscoveryHumansMiceRetrospective StudiesSchwann CellsSciatic NerveConceptsDiabetic peripheral neuropathySchwann cellsPeripheral neuropathyPeripheral nervous systemPrimary Schwann cellsBupropion treatmentDiabetic patientsMyelin damageSensory dysfunctionPrimary gliaSelective vulnerabilityAntidepressant drugsHyperglycemic miceLower incidenceRetrospective analysisHuman pluripotent stem cellsSC deathNervous systemTherapeutic candidateHigh glucoseNeuropathyHealth recordsMolecular featuresStem cellsPluripotent stem cells